Literature DB >> 22129983

Personalized medicine in oncology: next generation.

Alex Chiang, Ryan P Million.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22129983     DOI： 10.1038/nrd3603

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  4 in total

1.  AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.

Authors:  Samir N Khleif; James H Doroshow; William N Hait
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

2.  Impact of genetic diagnostics on drug development strategy.

Authors:  Ryan P Million
Journal:  Nat Rev Drug Discov       Date:  2006-05-12       Impact factor: 84.694

3.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

Review 4.  The microeconomics of personalized medicine: today's challenge and tomorrow's promise.

Authors:  Jerel C Davis; Laura Furstenthal; Amar A Desai; Troy Norris; Saumya Sutaria; Edd Fleming; Philip Ma
Journal:  Nat Rev Drug Discov       Date:  2009-03-20       Impact factor: 84.694
  4 in total
  9 in total

1.  Should UK primary care be an early adopter of genomic medicine?

Authors:  Donna Dickenson; Imran Rafi; John Spicer; Andrew Papanikitas
Journal:  Br J Gen Pract       Date:  2019-07       Impact factor: 5.386

2.  Nano-polypharmacy to treat tumors: coencapsulation of drug combinations using nanoparticle technology.

Authors:  Frank Alexis
Journal:  Mol Ther       Date:  2014-07       Impact factor: 11.454

Review 3.  Computational algorithms for in silico profiling of activating mutations in cancer.

Authors:  E Joseph Jordan; Keshav Patil; Krishna Suresh; Jin H Park; Yael P Mosse; Mark A Lemmon; Ravi Radhakrishnan
Journal:  Cell Mol Life Sci       Date:  2019-04-13       Impact factor: 9.261

4.  [Health economic aspects of a stratified medicine for rheumatoid arthritis].

Authors:  M Frank; T Mittendorf
Journal:  Z Rheumatol       Date:  2013-02       Impact factor: 1.372

5.  Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models.

Authors:  Rhonda Greenapple
Journal:  Am Health Drug Benefits       Date:  2012-07

Review 6.  Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.

Authors:  Martin Frank; Thomas Mittendorf
Journal:  Pharmacoeconomics       Date:  2013-03       Impact factor: 4.981

7.  Kinotypes: stable species- and individual-specific profiles of cellular kinase activity.

Authors:  Brett Trost; Jason Kindrachuk; Erin Scruten; Philip Griebel; Anthony Kusalik; Scott Napper
Journal:  BMC Genomics       Date:  2013-12-05       Impact factor: 3.969

8.  A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.

Authors:  Dee Luo; James A Smith; Nick A Meadows; A Schuh; Katie E Manescu; Kim Bure; Benjamin Davies; Rob Horne; Mike Kope; David L DiGiusto; David A Brindley
Journal:  Front Genet       Date:  2016-01-28       Impact factor: 4.599

Review 9.  A review of the application of machine learning in molecular imaging.

Authors:  Lin Yin; Zhen Cao; Kun Wang; Jie Tian; Xing Yang; Jianhua Zhang
Journal:  Ann Transl Med       Date:  2021-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.